4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

Georgina V. Long; Jacob Schachter; Antoni Ribas; Ana M. Arance; Jean-Jacques Grob; Laurent Mortier; Adil Daud; Matteo S. Carlino; Catriona M. McNeil; Michal Lotem; James M. G. Larkin; Paul Lorigan; Bart Neyns; Christian U. Blank; Teresa M. Petrella; Omid Hamid; James Anderson; Clemens Krepler; Nageatte Ibrahim; Caroline Robert

doi:10.1200/jco.2018.36.15_suppl.9503

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

Georgina V. Long, Jacob Schachter, Antoni Ribas, Ana M. Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James M. G. Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, James Anderson, Clemens Krepler, Nageatte Ibrahim, Caroline Robert

Research output: Contribution to conference › Abstract › peer-review

Abstract

9503
Background: KEYNOTE-006 (NCT01866319) established superiority of pembro over ipi in advanced melanoma. We provide 4-y outcomes, long-term data for pts who completed 2 y pembro, and data for sec...

Original language	English
Pages	9503-9503
Number of pages	1
DOIs	https://doi.org/10.1200/jco.2018.36.15_suppl.9503
Publication status	Published - 20 May 2018

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/jco.2018.36.15_suppl.9503

Cite this

Long, G. V., Schachter, J., Ribas, A., Arance, A. M., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., Larkin, J. M. G., Lorigan, P., Neyns, B., Blank, C. U., Petrella, T. M., Hamid, O., Anderson, J., Krepler, C., Ibrahim, N., & Robert, C. (2018). 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.. 9503-9503. https://doi.org/10.1200/jco.2018.36.15_suppl.9503

@conference{486e398e5b3240eca08667262bc6d537,

title = "4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.",

abstract = "9503Background: KEYNOTE-006 (NCT01866319) established superiority of pembro over ipi in advanced melanoma. We provide 4-y outcomes, long-term data for pts who completed 2 y pembro, and data for sec...",

author = "Long, {Georgina V.} and Jacob Schachter and Antoni Ribas and Arance, {Ana M.} and Jean-Jacques Grob and Laurent Mortier and Adil Daud and Carlino, {Matteo S.} and McNeil, {Catriona M.} and Michal Lotem and Larkin, {James M. G.} and Paul Lorigan and Bart Neyns and Blank, {Christian U.} and Petrella, {Teresa M.} and Omid Hamid and James Anderson and Clemens Krepler and Nageatte Ibrahim and Caroline Robert",

year = "2018",

month = may,

day = "20",

doi = "10.1200/jco.2018.36.15_suppl.9503",

language = "English",

pages = "9503--9503",

}

Long, GV, Schachter, J, Ribas, A, Arance, AM, Grob, J-J, Mortier, L, Daud, A, Carlino, MS, McNeil, CM, Lotem, M, Larkin, JMG, Lorigan, P, Neyns, B, Blank, CU, Petrella, TM, Hamid, O, Anderson, J, Krepler, C, Ibrahim, N & Robert, C 2018, '4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.', pp. 9503-9503. https://doi.org/10.1200/jco.2018.36.15_suppl.9503

TY - CONF

T1 - 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

AU - Long, Georgina V.

AU - Schachter, Jacob

AU - Ribas, Antoni

AU - Arance, Ana M.

AU - Grob, Jean-Jacques

AU - Mortier, Laurent

AU - Daud, Adil

AU - Carlino, Matteo S.

AU - McNeil, Catriona M.

AU - Lotem, Michal

AU - Larkin, James M. G.

AU - Lorigan, Paul

AU - Neyns, Bart

AU - Blank, Christian U.

AU - Petrella, Teresa M.

AU - Hamid, Omid

AU - Anderson, James

AU - Krepler, Clemens

AU - Ibrahim, Nageatte

AU - Robert, Caroline

PY - 2018/5/20

Y1 - 2018/5/20

N2 - 9503Background: KEYNOTE-006 (NCT01866319) established superiority of pembro over ipi in advanced melanoma. We provide 4-y outcomes, long-term data for pts who completed 2 y pembro, and data for sec...

AB - 9503Background: KEYNOTE-006 (NCT01866319) established superiority of pembro over ipi in advanced melanoma. We provide 4-y outcomes, long-term data for pts who completed 2 y pembro, and data for sec...

UR - http://www.mendeley.com/research/4year-survival-outcomes-after-cessation-pembrolizumab-pembro-after-2years-patients-pts-ipilimumab-ip

U2 - 10.1200/jco.2018.36.15_suppl.9503

DO - 10.1200/jco.2018.36.15_suppl.9503

M3 - Abstract

SP - 9503

EP - 9503

ER -

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

Abstract

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this